Occupational Therapists in New Iberia, LA Accepting Medicare

6 Occupational Therapists found. Showing 1 - 6

Karlyn Meyers, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 Rue De Brille, New Iberia, LA 70563 Phone: 337-364-5467    Fax: 337-365-3233

Mrs. Alyria Wilson, MOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 138 E Main St, New Iberia, LA 70560 Phone: 337-578-2562

Prof. Regina Champagne Blanchard, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1307 Old Jeanerette Rd, New Iberia, LA 70563 Phone: 337-367-3331    Fax: 337-367-6494

Danielle L. Rose, O.T. Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 600 Rue De Brille, New Iberia, LA 70563 Phone: 337-364-5467    Fax: 337-365-3233

Laura Dubea, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 138 E Main St, New Iberia, LA 70560 Phone: 337-359-8748

Prof. Cathy Chapman Gauthier, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1307 Old Jeanerette Rd, New Iberia, LA 70563 Phone: 337-367-3331    Fax: 367-367-6494

News Archive

Senate Budget Committee approves FY 2011 budget resolution with cuts to foreign aid

The Senate Budget Committee has approved a budget resolution that adheres to President Barack Obama's "proposal to freeze non-defense spending, then goes a bit further" with cuts to "the State Department and other international programs," the Washington Post reports (Montgomery, 4/23).

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

Almirall strengthens its respiratory franchise with a new generation of Chronic Obstructive Pulmonary Disease (COPD) treatment

Almirall strengthens its position in the respiratory field with a positive development progress of another New Chemical Entity (NCE). LAS190792 is a new dual long-acting Muscarinic Antagonist β2 Agonist (MABA), which combines two bronchodilator mechanisms in a single molecule for the treatment of COPD.

Examining health sector funding agreement between Liberia, USAID

"[A] new and complementary agreement between Liberia and USAID, called the Fixed Amount Reimbursement Agreement (FARA)," is "quite revolutionary," Amanda Glassman, director of global health policy and a research fellow at the Center for Global Development (CGD), and Jacob Hughes, write in CGD's "Global Health Policy" blog.

Read more Medical News

› Verified 1 days ago